Пульс - медицинский центр 
Пульс - медицинский центр
Круглосуточно
бесплатно по России
+7 (965) 177 17 74
бесплатно по России
The criteria for assessing their own health by young people (25-44 years old - according to the WHO classification) were distributed as follows: almost half of the respondents, regardless of gender, rated their own health as "good"; every 4th of those surveyed - as "very good"; “Mediocre” health was noted by every fifth woman and every tenth person; almost the same was the proportion of respondents who rated their own health as “bad”; the level of subjective assessment of "excellent health" was observed in every tenth man, while in women it was absent.
Сульфасалазин и 5-аминосалицилат Препараты 5-АСК обладают очень слабой иммуносупрессивной активностью. Нет сообщений о том, что эти препараты связаны с повышенным риском инфицирования, а исследования, оценивающие профиль безопасности 5-АСК, не демонстрируют повышенного риска серьезных или оппортунистических инфекций. Лечение 5-АСК следует продолжать, не беспокоясь о повышенном риске заражения или развития тяжелой формы COVID-19 . Если пациент находится в контакте с больным COVID-19 или у него развивается COVID-19, лечение 5-АСК следует продолжить.
In regions where there are no active hostilities, it is necessary to intensify the process of polio vaccination of both local and displaced children under 6 years of age with an additional dose of inactivated vaccine and continue vaccination by age in accordance with the Immunization Schedule against all infectious diseases controlled by specific means. For the prevention of poliomyelitis, preference should be given to an inactivated vaccine for all
5-ASA preparations have very weak immunosuppressive activity. There are no reports that these drugs are associated with an increased risk of infection, and studies evaluating the safety profile of 5-ASA do not show an increased risk of serious or opportunistic infections. Treatment with 5-ASA should be continued without concern for an increased risk of infection or severe COVID-19. If the patient is in contact with a patient with COVID-19 or develops COVID-19, treatment with 5-ASA should be continued.
Закажите обратный звонок
Задать вопрос
Быстрая запись на прием